Patents Assigned to Diamyd Medical AB
  • Formulation of gamma-aminobutyric acid
    Patent number: 11638701
    Abstract: The present invention relates to an oral dosage form comprising gamma-aminobutyric acid (GABA) and pharmaceutically acceptable excipients, wherein 100% of the GABA is released within 0.25-5 hours in 0.01 M HCl at 37° C. in a USP dissolution apparatus 2. The invention further relates to specific dosage forms, methods for treatment of autoimmune diseases with the dosage form, as well as use of the dosage form in such methods.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: May 2, 2023
    Assignee: DIAMYD MEDICAL AB
    Inventors: Anton Lindqvist, Ulf Hannelius
  • IMMUNOMODULATION FOR AUTOIMMUNE TYPE-2 DIABETES
    Publication number: 20090252753
    Abstract: The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant.
    Type: Application
    Filed: March 20, 2009
    Publication date: October 8, 2009
    Applicant: Diamyd Medical AB
    Inventors: John Robertson, Anders Essen-Moller
  • Methods and kits useful for determining the status of and detecting pancreatic B-cell associated autoimmune diseases
    Patent number: 6455267
    Abstract: Isolated polypeptides useful in ameliorating GAD-associated autoimmune disease as well as diagnostic and therapeutic methods of using the peptides are disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 24, 2002
    Assignees: Diamyd Medical AB, RSR Limited, Perkin Elmer Life Sciences
    Inventors: Allan J. Tobin, Mark G. Erlander, Daniel L. Kaufman